Dr. Schuster is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3400 Civic Center Blvd
Perelman Center for Advanced Medicine, 12th Floor
Philadelphia, PA 19104Phone+1 215-662-3914- Is this information wrong?
Summary
- Dr. Stephen Schuster is a hematologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center. He received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has been in practice 36 years. He specializes in hematologic oncology and is experienced in hematologic oncology and leukemia. He has more than 100 publications and over 500 citings.
Education & Training
- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1988 - 1988
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 1984 - 1988
- Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 1981 - 1984
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1981
Certifications & Licensure
- PA State Medical License 1982 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2011-2014
- Philadelphia Magazine Castle Connolly, 2010-2014
- America's Top Doctors for Cancer Castle Connolly, 2010-2013
- Join now to see all
Clinical Trials
- Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma Start of enrollment: 2000 Jan 01
- Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant Start of enrollment: 2007 Feb 01
- Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas Start of enrollment: 2008 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C Chavez, Emmanuel...> ;Blood. 2024 Apr 25
- Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.Guido Ghilardi, Luca Paruzzo, Vrutti Patel, Jakub Svoboda, Emeline R Chong, Eugenio Fardella, Elise A Chong, Giulia Gabrielli, Sunita D Nasta, Daniel J Landsburg, Jord...> ;Journal of Hematology & Oncology. 2024 Apr 22
- Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.Lihua E Budde, Sarit Assouline, Laurie H Sehn, Stephen J Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, ...> ;Journal of Clinical Oncology. 2024 Mar 28
- Join now to see all
Journal Articles
- LRPAP1 Is a Frequent Proliferation-Inducing Antigen of BCRs of Mantle Cell Lymphomas and Can Be Used for Specific Therapeutic TargetingStephen J Schuster, Mariusz Wasik, Nature
- Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United StatesArun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica
- Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin LymphomaStephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood
Abstracts/Posters
- Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's MacroglobulinemiaStephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...Stephen J Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release SpecificationsStephen J. Schuster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clinical Outcomes of Venetoclax Therapy in Patients with Relapsed/Refractory (r/r) Non Hodgkin Lymphomas (NHL)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Around the Nation: FDA Grants Expanded Approval for CAR-T TherapyJune 2nd, 2022
- FDA Approves Novartis Kymriah® CAR-T Cell Therapy for Adult Patients with Relapsed or Refractory Follicular LymphomaMay 28th, 2022
- Collaboration Between Rheumatologists, Primary Care Reduces Delay in Axial SpA DiagnosisAugust 4th, 2021
- Join now to see all
Hospital Affiliations
- Hospital of the University of PennsylvaniaPhiladelphia, Pennsylvania
- Penn Presbyterian Medical CenterPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: